Literature DB >> 2073986

Assessment of precision, concordance, specificity, and sensitivity of islet cell antibody measurement in 41 assays.

E Bonifacio1, C Boitard, H Gleichmann, M A Shattock, J L Molenaar, G F Bottazzo.   

Abstract

Forty-one assays were analysed at the 3rd International Workshop on the standardisation of islet cell antibodies. Analysis of precision demonstrated assays consistently detecting blind duplicates within one doubling dilution and capable of discriminating one doubling dilution differences in islet cell antibody concentration. Some assays, however, reported duplicates discrepantly by more than seven doubling dilutions, and consequently could not distinguish even large quantities of islet cell antibodies. Precision was best in assays from laboratories which had participated in all three Standardisation Workshops and was not dependent upon methodology. The use of the Juvenile, Diabetes Foundation reference islet cell antibody standard and standard curves reduced the scatter of results, and was best amongst assays with better precision. Twenty-seven assays reported all ten blood donor sera as negative. However, 14 assays did not, and specificity (negativity in health) was less than 50% in three assays. Low specificity was strongly associated with poor precision. The detection limit of assays ranged from less than 5 to 50 JDF units and was partially dependent upon methodology. Assays incorporating extended incubation had the lowest detection limits without a decrease in the specificity of the ten blood donor sera. Precise quantification is fundamental for the standardisation and comparability of islet cell antibodies. Precise quantitative assays have been identified and reference standards and common units established.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2073986     DOI: 10.1007/BF00400345

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  22 in total

1.  Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies.

Authors:  G F Bottazzo; A Florin-Christensen; D Doniach
Journal:  Lancet       Date:  1974-11-30       Impact factor: 79.321

2.  Antinuclear antibody. Precise and accurate quantitation without serial dilution.

Authors:  E Bonifacio; P N Hollingsworth; R L Dawkins
Journal:  J Immunol Methods       Date:  1986-07-24       Impact factor: 2.303

3.  Serum exchange and use of dilutions have improved precision of measurement of islet cell antibodies.

Authors:  E Bonifacio; A Lernmark; R L Dawkins
Journal:  J Immunol Methods       Date:  1988-01-21       Impact factor: 2.303

4.  The value of islet cell antibody in predicting secondary failure of oral hypoglycaemic agent therapy in Diabetes mellitus.

Authors:  W J Irvine; J S Sawers; C M Feek; R J Prescott; L J Duncan
Journal:  J Clin Lab Immunol       Date:  1979-04

5.  Expression of cytoplasmic islet cell antigens by rat pancreas.

Authors:  S A Dib; P G Colman; F Dotta; M Tautkus; A Rabizadeh; G S Eisenbarth
Journal:  Diabetes       Date:  1987-08       Impact factor: 9.461

6.  Correlation of islet cell antibodies and HLA-DR phenotypes with diabetes mellitus in adults.

Authors:  H Gleichmann; B Zörcher; B Greulich; F A Gries; H R Henrichs; J Betrams; H Kolb
Journal:  Diabetologia       Date:  1984-07       Impact factor: 10.122

7.  A two-colour immunofluorescence test with a monoclonal human proinsulin antibody improves the assay for islet cell antibodies.

Authors:  O D Madsen; M L Olsson; G Bille; G Sundkvist; A Lernmark; G Dahlqvist; J Ludvigsson
Journal:  Diabetologia       Date:  1986-02       Impact factor: 10.122

8.  The prevalence of islet cell antibodies in Japanese insulin-dependent and non-insulin-dependent diabetic patients studied by indirect immunofluorescence and by a new method.

Authors:  T Kobayashi; T Sugimoto; T Itoh; K Kosaka; T Tanaka; S Suwa; K Sato; K Tsuji
Journal:  Diabetes       Date:  1986-03       Impact factor: 9.461

9.  Disappearance and reappearance of islet cell cytoplasmic antibodies in cyclosporin-treated insulin-dependent diabetics.

Authors:  T Mandrup-Poulsen; J Nerup; C R Stiller; B Marner; G Bille; D Heinrichs; R Martell; J Dupre; P A Keown; M R Jenner
Journal:  Lancet       Date:  1985-03-16       Impact factor: 79.321

10.  Increased reduction in fasting C-peptide is associated with islet cell antibodies in type 1 (insulin-dependent) diabetic patients.

Authors:  B Marner; T Agner; C Binder; A Lernmark; J Nerup; T Mandrup-Poulsen; S Walldorff
Journal:  Diabetologia       Date:  1985-12       Impact factor: 10.122

View more
  19 in total

1.  Early T-cell defects in pre-type 1 diabetes.

Authors:  L al Sakkaf; P Pozzilli; P J Bingley; M W Lowdell; J M Thomas; E Bonifacio; E A Gale; G F Bottazzo
Journal:  Acta Diabetol       Date:  1992       Impact factor: 4.280

2.  Fifth International Serum Exchange Workshop for Insulin Autoantibody (IAA) Standardization. The Immunology and Diabetes Workshops and participating laboratories.

Authors:  C J Greenbaum; T J Wilkin; J P Palmer
Journal:  Diabetologia       Date:  1992-08       Impact factor: 10.122

3.  An immunological and genetic study of patients with gestational diabetes mellitus.

Authors:  A Lapolla; C Betterle; M Sanzari; R Zanchetta; E Pfeifer; A Businaro; U Fagiolo; M Plebani; S Marini; E Photiou; D Fedele
Journal:  Acta Diabetol       Date:  1996-07       Impact factor: 4.280

4.  Assignment of islet cell antibody titres and selection of subjects for IDDM prevention trials.

Authors:  J Morales; M Puig-Domingo; D Mauricio; A De Leiva
Journal:  Diabetologia       Date:  1995-05       Impact factor: 10.122

Review 5.  Autoantibodies in insulin-dependent diabetes mellitus.

Authors:  E Bosi; E Bonifacio
Journal:  J Endocrinol Invest       Date:  1994 Jul-Aug       Impact factor: 4.256

6.  Islet cell antibodies predict insulin-dependent diabetes in United States school age children as powerfully as in unaffected relatives.

Authors:  D Schatz; J Krischer; G Horne; W Riley; R Spillar; J Silverstein; W Winter; A Muir; D Derovanesian; S Shah
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

7.  Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity.

Authors:  E Bonifacio; S Genovese; S Braghi; E Bazzigaluppi; V Lampasona; P J Bingley; L Rogge; M R Pastore; E Bognetti; G F Bottazzo
Journal:  Diabetologia       Date:  1995-07       Impact factor: 10.122

8.  Proinsulin autoantibodies are more closely associated with type 1 (insulin-dependent) diabetes mellitus than insulin autoantibodies.

Authors:  K Böhmer; H Keilacker; B Kuglin; A Hübinger; J Bertrams; F A Gries; H Kolb
Journal:  Diabetologia       Date:  1991-11       Impact factor: 10.122

9.  Detection of autoantibodies against islet amyloid polypeptide in human serum. Lack of association with type 1 (insulin-dependent) diabetes mellitus, or with conditions favouring amyloid deposition in islets. The Belgian Diabetes Registry.

Authors:  F K Gorus; J C Sodoyez; D G Pipeleers; B Keymeulen; A Foriers; C F Van Schravendijk
Journal:  Diabetologia       Date:  1992-11       Impact factor: 10.122

10.  Islet cell antibody heterogeneity among type 1 (insulin-dependent) diabetic patients.

Authors:  J Timsit; S Caillat-Zucman; H Blondel; P Chédin; J F Bach; C Boitard
Journal:  Diabetologia       Date:  1992-08       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.